Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Jun 3;14(3):331–343. doi: 10.1007/s10456-011-9217-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2011

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Fig. 3 — Effect of combined EAF2- and VHL-deficiency on the prostate at age 20–24 mos. a Body mass. b Absolute prostate mass. c Relative prostate mass. Data represent average of 4–8 mice per group (P > 0.05). d Incidence rate of prostatic intraepithelial neoplasia (*P < 0.05). e H&E stain of transverse sections of prostate ventral lobes from wild-type control (WT), EAF2^−/−, VHL^+/− and EAF2^−/−VHL^+/− mice at age 20–24 mos. All groups displayed increased lymphocytic infiltration (black arrow, WT inset). EAF2^−/− mice displayed prostatic intraepithelial neoplasia (black arrow), stromal fibrosis and fibroplasia (dashed arrow) and stromal edema (red arrow). VHL^+/− mice displayed lymphocytic infiltration (black arrow), stromal fibrosis and fibroplasia (dashed arrow), but not prostatic intraepithelial neoplasia. EAF2^−/−VHL^+/− mice displayed prostatic intraepithelial neoplasia (black arrow), stromal fibrosis and fibroplasia (dashed arrow) and stromal edema (red arrow)